Parenterale Darreichungsformen von Antiviralen Helicase-Primase-Hemmern
EP4806434
16. September 2026
Anmelder: Innovative Molecules GmbH 🇩🇪
Details
- Veröffentlichungs-Nr.
- EP4806434
- Anmeldetag
- 13. März 2025
- Veröffentlichung
- 16. September 2026
- Rechtsraum
- EP
Abstract
The invention relates to pharmaceutical compositions comprising a compound according to Formula (I)acting as a helicase-primase inhibitor, including its isotopic variants and pharmaceutically acceptable salts, co-crystals, hydrates and solvates thereof, and one or more cyclodextrins and the use thereof in the prophylaxis and treatment of herpes infections and mediated diseases.
Anmelder
- Firma
- Innovative Molecules GmbH
- Land
- 🇩🇪 Deutschland